SEC Form 4 · accession 0001062993-18-003472
Lexaria Bioscience Corp. · LXRP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Bunka
Officer — CEO · Director · 10% Owner
Period of report
Jan 20, 2010
Accepted (ET)
Aug 16, 2018 · 3:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348362
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Aug 14, 2018 | G | 500,000 | — | D | 7,093,804 | D | |
| Common Shares | holding | — | — | — | 6,081,844 | I | Private holding company | |
| Common Shares | holding | — | — | — | 7,593,804 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options | $0.10 | holding | — | — | — | Dec 23, 2014 | Dec 23, 2019 | Common Shares | 550,000 | 550,000 | D |
| Stock Options | $1.53 | holding | — | — | — | May 31, 2018 | May 31, 2023 | Common Shares | 700,000 | 1,250,000 | D |
Explanation of responses
- F1Consisted of a Charitable Donation to a registered non-profit organization